# US 2016/0235834 A1 · Live attenuated vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235834 A1
- Document ID: US20160235834A1
- Status: Published application
- Kind: A1
- Application number: 15/028,176
- Filed: 2014-10-13
- Published: 2016-08-18
- Earliest claimed: 2013-10-11
- Assignees: Servicio Galego de Saude (Sergas); FundacióN Profesor Novoa Santos
- Applicants: Servicio Galego De SAúDe (Sergas); FundacióN Profesor Novoa Santos
- Inventors: Germán Bou Arévalo; María Clara Póvoa Cabral; Astrid Pèrez Gómez; María Merino Carballeira; Alejandro Beceiro Casas; Patricia García Fernández
- Web page: https://patentgrep.com/patent/US20160235834A1

## CPC

- A61K 39/104: {Pseudomonadales, e.g.} Pseudomonas
- A61K 39/085: Staphylococcus
- A61K 39/1045: {Moraxella}
- A61P 31/04: Antibacterial agents
- C07K 16/1214: Pseudomonadaceae (F)
- C07K 16/1217: Neisseriaceae (F)
- C07K 16/1218: Acinetobacter (G)
- C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- C12N 1/205: Bacterial isolates
- C12N 1/36: Adaptation or attenuation of cells
- C12N 9/1096: {transferring nitrogenous groups (2.6)}
- C12N 9/90: Isomerases (5.)
- G01N 33/56911: {Bacteria}
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/575: {humoral response}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- C12R 2001/385: Pseudomonas aeruginosa
- C12R 2001/445: Staphylococcus aureus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wail, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.

## Claims

### Claim 1

A method for the production of a pharmaceutical composition, preferably a vaccine, comprising mutant live auxotrophic bacterial strains for D-glutamate, wherein the pharmaceutical composition is suitable for the prophylactic treatment (before infection) and/or therapeutic treatment (after infection or after the clinical manifestation of the disease caused by the infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition, and wherein said pharmaceutical composition is produced by a method comprising the steps of:
a. obtaining mutant live auxotrophic bacterial strains for D-glutamate;
b. introducing said mutant live auxotrophic bacerial strains in a pharmaceutically acceptable carrier or diluent and optionally adding an adjuvant; and
c. Optionally freeze-drying the pharmaceutical composition.

### Claim 2

A method for the production of a pharmaceutical composition, preferably a vaccine, comprising mutant live auxotrophic bacterial strains for D-glutamate, wherein the pharmaceutical composition is suitable for the prophylactic (before infection) and/or therapeutic treatment (after infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition, and wherein said pharmaceutical composition is produced by a method comprising the steps of:
a. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wall;
b. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase, wherein the inactivation of said genes thus causes said bacterial strain to be auxotrophic for D-glutamate; and
c. introducing said mutant live auxotrophic bacterial strains in a pharmaceutically acceptable carrier or diluent and optionally adding an adjuvant; and
d. Optionally freeze-drying the pharmaceutical composition.

### Claim 3 (depends on 1, 2, 3)

The method for the production of a pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition is a vaccine and the production method comprises adding an adjuvant. 4, The method of any of claims 1-3, wherein the bacterial strain of step a) is a gram positive or gram negative bacteria.

### Claim 5 (depends on 2)

The method of claim 2, wherein the bacterial strain of step a) has as the only way of synthesis of D-glutamate the glutamate racemase enzyme and wherein step b) of the method comprises the inactivation of the genes encoding for this enzyme, namely for glutamate racemase.

### Claim 6 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the bacterial strain of step a) is selected from the list of bacterial species consisting of: Acinetobacter baumannii, Acinetobacter baylyi, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Acinetobacter junii, Acinetobacter lwoffii, Acinetobacter nosocomialis, Acinetobacter pittii, Acinetobacter radioresistens, Actinobacillus lignieresii, Actinobacillus suis, Aeromonas caviae, Aeromonas hydrophila, Aeromonas veronii subsp. sobria, Aggregatibacter actinomycetemcomitans, Arcobacter butzleri, Arcobacter nitrofigilis, Bacillus amyloliquefaciens, Bacillus anthracis, Bacillus bataviensis, Bacillus cellulosilyticus, Bacillus cereus, Bacillus clausil, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus subtilis, Bacillus thuringiensis, Bacteroides fragilis, Bordetella avium, Bordetella bronchiseptica, Bordetella pertusis, Bordetella petrii, Brucella abortus, Brucella melitensis, Brucella suis, Burkholderia cenocepacia, Burkholderia mallei, Burkholderia multivorans, Burkholderia pseudomallei, Burkholderia thailandensis, Campylobacter concisus, Campylobacter fetus subsp. fetus, Campylobacter fetus subsp. venerealis, Campylobacter gracilis, Campylobacter hominis, Campylobacter jejuni, Campylobacter rectus, Campylobacter showae, Campylobacter upsaliensis, Citrobacter freundii, Citrobacter koseri, Clostridium asparagiforme, Clostridium botulinum, Clostridium butyricum, Clostridium difficile, Clostridium perfringens, Clostridium saccharobutylicum, Clostridium tetani, Corynebacterium diphtheriae, Corynebacterium pseudotuberculosis, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Escherichia coli, Fusobacterium necrophorum, Fusobacterium nucleatum, Granulicatella adiacens, Granulicatella elegans, Haemophilus equigenitalis, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus paragaffinarum, Haemophilus parasuis, Haemophilus pleuropneumoniae, Haemophilus somnus, Helicobacter pylori, Klebsiella oxytoca, Klebsiella pneumoniae, Legionella oakridgensis, Legionella pneumophila, Leptospira biflexa, Leptospira illini, Leptospira interrogans, Listeria monocytogenes, Lysinibacillus fusiformis, Lysinibacillus sphaericus, Moraxella bovis, Morganella morganii, Mycobacterium abscessus, Mycobacterium africanum, Mycobacterium avium, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Plesiomonas shigelloides, Propionibacterium acnes, Proteus hanseri, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella cholerasuis, Salmonella enterica subsp. enterica, Salmonella enteritidis, Salmonella paratyphi, Salmonella typhi, Serratia plymuthica, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus capitis, Staphylococcus caprae, Staphylococcus carnosus, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus pettenkoferi, Staphylococcus pseudointermedius, Staphylococcus saprophyticus, Staphylococcus simiae, Staphylococcus simulans, Staphylococcus warneri, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus dysgalactiae subsp. equisimilis, Streptococcus equi, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus uberis, Streptococcus zooepidermicus, Taylorella asinigenitalis, Taylorella equigenitalis, Treponema carateum, Treponema cuniculi, Treponema hyodisenteriae, Treponema pallidum, Treponema suis, Veillonella atypica, Veillonella dispar, Veillonella parvula, Veillonella ratti, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and Yersinia pseudotuberculosis..

### Claim 7 (depends on 6)

The method of claim 6, wherein said bacterial strain of step a) is selected from the list consisting of the following species: Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus.

### Claim 8 (depends on 7)

The method of claim 7, wherein said bacterial strain of step a) is the bacterial strain of A. baumannii designated Acinetobacter baumannii Delta0380/Delta3398 and deposited under the Budapest treaty before the Spanish Type Culture Collection on Apr. 14, 2014 with strain number 8588 by Fundación Profesor Novoa Santos.

### Claim 9 (depends on 7)

The method of claim 7 wherein said bacterial strain of step a) is the bacterial strain of P. aeruginosa designated Pseudomonas aeruginosa DeltaPA4662 and deposited under the Budapest treaty before the Spanish Type Culture Collection on Apr. 14, 2014 with strain number 8589 by Fundación Profesor Novoa Santos.

### Claim 10 (depends on 7)

The method of claim 7 wherein said bacterial strain of step a) is the bacterial strain of S. aureus designated 132deltamurl/deltadat and deposited under the Budapest treaty before the Spanish Type Culture Collection on Jun. 11, 2014 with strain number 8587 by Fundación Profesor Novoa Santos.

### Claim 11

A pharmaceutical composition, preferably a vaccine, comprising mutant live auxotrophic bacerial strains for D-glutamate and a pharmaceutically acceptable carrier or diluent and optionally an adjuvant, wherein said pharmaceutical composition is suitable for the prophylactic (before infection) and/or therapeutic treatment (after infection or after the clinical manifestation of the disease caused by the infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein said pharmaceutical composition is a vaccine and wherein optionally said vaccine comprises an adjuvant.

### Claim 13 (depends on 11, 12)

The pharmaceutical composition of any of claims 11 to 12, wherein said pharmaceutically acceptable carrier or diluent is selected from the list consisting of water, culture fluid, a solution of physiological salt concentration and/or stabilisers such as SPGA, carbohydrates (e.g. sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein containing agents such as bovine serum or skimmed milk and buffers (e.g. phosphate buffer).

### Claim 14 (depends on 11, 12, 13)

The pharmaceutical composition of any of claims 11 to 13, wherein the adjuvant is selected from the list consisting of Freunds Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers, muramyldipeptides, ISCOMs (immune stimulating complexes), Saponins, mineral oil, vegetable oil, Carbopol, the E. coli heat-labile toxin (LT) or Cholera toxin (CT), aluminium hydroxide, aluminium phosphate or aluminium oxide, oil-emulsions (e.g. of Bayol F® or Marcol 52®, saponins and vitamin-E solubilisate.

### Claim 15 (depends on 11, 12, 13, 14)

The pharmaceutical composition of any of claims 11 to 14, wherein said pharmaceutical composition comprises a dose of mutant live auxotrophic bacterial strains for D-glutamate ranging between 103 and 1010 bacteria.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The pharmaceutical composition of any of claims 11 to 15, wherein said pharmaceutical composition is in a freeze-dried form.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The pharmaceutical composition of any of claims 11 to 16, wherein the bacterial strain is selected from the list of bacterial species consisting of: Acinetobacter baumannii, Acinetobacter baylyi, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Acinetobacter junii, Acinetobacter lwoffii, Acinetobacter nosocomialis, Acinetobacter pittii, Acinetobacter radioresistens, Actinobacillus lignieresii, Actinobacillus suis, Aeromonas caviae, Aeromonas hydrophila, Aeromonas veronii subsp. sobria, Aggregatibacter actinomycetemcomitans, Arcobacter butzleri, Arcobacter nitrofigilis, Bacillus amyloliquefaciens, Bacillus anthracis, Bacillus bataviensis, Bacillus cellulosilyticus, Bacillus cereus, Bacillus clausii, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus subtilis, Bacillus thuringiensis, Bacteroides fragilis, Bordetella avium, Bordetella bronchiseptica, Bordetella pertusis, Bordetella petrii, Brucella abortus, Brucella melitensis, Brucella suis, Burkholderia cenocepacia, Burkholderia mallei, Burkholderia multivorans, Burkholderia pseudomallei, Burkholderia thailandensis, Campylobacter concisus, Campylobacter fetus subsp. fetus, Campylobacter fetus subsp. venerealis, Campylobacter gracilis, Campylobacter hominis, Campylobacter jejuni, Campylobacter rectus, Campylobacter showae, Campylobacter upsaliensis, Citrobacter freundii, Citrobacter koseri, Clostridium asparagiforme, Clostridium botulinum, Clostridium butyricum, Clostridium difficile, Clostridium perfringens, Clostridium saccharobutylicum, Clostridium tetani, Corynebacterium diphtheriae, Corynebacterium pseudotuberculosis, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Escherichia coli, Fusobacterium necrophorum, Fusobacterium nucleatum, Granulicatella adiacens, Granulicatella elegans, Haemophilus equigenitalis, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus paragallinarum, Haemophilus parasuis, Haemophilus pleuropneumoniae, Haemophilus somnus, Helicobacter pylon, Klebsiella oxytoca, Klebsiella pneumoniae, Legionella oakridgensis, Legionella pneumophila, Leptospira biflexa, Leptospira Leptospira interrogans, Listeria monocytogenes, Lysinibacillus fusiformis, Lysinibacillus sphaericus, Moraxella bovis, Morganella morganii, Mycobacterium abscesses, Mycobacterium africanum, Mycobacterium avium, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Plesiomonas shigelloides, Propionibacterium acnes, Proteus hanseri, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella cholerasuis, Salmonella enterica subsp. enterica, Salmonella enteritidis, Salmonella paratyphi, Salmonella typhi, Serratia plymuthica, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus capitis, Staphylococcus caprae, Staphylococcus carnosus, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus pettenkoferi, Staphylococcus pseudointermedius, Staphylococcus saprophyticus, Staphylococcus simiae, Staphylococcus simulans, Staphylococcus warneri, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus dysgalactiae subsp. equisimilis, Streptococcus equi, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus uberis, Streptococcus zooepidermicus, Taylorella asinigenitalis, Taylorella equigenitalis, Treponema carateum, Treponema cuniculi, Treponema hyodisenteriae, Treponema pallidum, Treponema suis, Veillonella atypica, Veillonella dispar, Veillonella parvula, Veillonella ratti, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and Yersinia pseudotuberculosis.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the bacterial strain is selected from the list consisting of the following species: Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the bacterial strain is the bacterial strain of A. baumannii designated Acinetobacter baumannii Delta0380/Delta3398 and deposited under the Budapest treaty before the Spanish Type Culture Collection on Apr. 14, 2014 with strain number 8588 by Fundación Profesor Novoa Santos.

### Claim 20 (depends on 18)

The pharmaceutical composition of claim 18, wherein the bacterial strain is is the bacterial strain of P. aeruginosa designated Pseudomonas aeruginosa DeltaPA4662 and deposited under the Budapest treaty before the Spanish Type Culture Collection on Apr. 14, 2014 with strain number 8589 by Fundación Profesor Novoa Santos.

### Claim 21 (depends on 18)

The pharmaceutical composition of claim 18, wherein the bacterial strain is is the bacterial strain of S. aureus designated . . . and deposited under the Budapest treaty before the Spanish Type Culture Collection on Apr. 14, 2014 with strain number . . . by Fundación Profesor Novoa Santos.

### Claim 22

A mutant live auxotrophic bacterial strain for D-glutamate, wherein said bacterial strain is the bacterial strain of P. aeruginosa designated Pseudomonas aeruginosa DeltaPA4662 and deposited under the Budapest treaty before the Spanish Type Culture Collection on Apr. 14, 2014 with strain number 8589 by Fundación Profesor Novoa Santos.

### Claim 23

A mutant live auxotrophic bacterial strain for D-glutamate, wherein said bacterial strain is the bacterial strain of S. aureus designated 132deltamurl/deltadat and deposited under the Budapest treaty before the Spanish Type Culture Collection on Jun. 11, 2014 with strain number 8587 by Fundación Profesor Novoa Santos.

### Claim 24 (depends on 22, 23)

The bacterial strain as defined in any of claim 22 or 23, for use as a medicament, in particular as a vaccine.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The pharmaceutical composition of any of claims 1 to 21 or the mutant live auxotrophic bacterial strain for D-glutamate of any of claim 22 or 23, for use in a method of prophylactic treatment (before infection) and/or therapeutic treatment (after infection or after the clinical manifestation of the disease caused by the infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition.

### Claim 26

An antibody or fragment thereof selected from the group consisting of Fab, F(ab′)2, Fv, scFv, di-scFv and sdAB, capable of recognizing a mutant live auxotrophic bacterial strain for D-glutamate, wherein said antibody or fragment thereof is suitable for the prophylactic treatment (before infection) and/or therapeutic treatment (after infection or after the clinical manifestation of the disease caused by the infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition.

### Claim 27

An antibody or fragment thereof selected from the group consisting of Fab, F(ab′)2, Fv, scFv, di-scFv and sdAB, obtained or obtainable after immunization of a mammal with a mutant live auxotrophic bacterial strain for D-glutamate, wherein said antibody or fragment thereof is suitable for the prophylactic treatment (before infection) and/or therapeutic treatment (after infection or after the clinical manifestation of the disease caused by the infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition

### Claim 28 (depends on 26, 27)

A pharmaceutical composition, preferably a vaccine, comprising the antibodies or fragments thereof of any of claim 26 or 27 and a pharmaceutically acceptable carrier or diluent and optionally an adjuvant, wherein said pharmaceutical composition is suitable for the prophylactic (before infection) and/or therapeutic treatment (after infection or after the clinical manifestation of the disease caused by the infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein said pharmaceutical composition is a vaccine and wherein optionally said vaccine comprises an adjuvant.

### Claim 30 (depends on 26, 27)

The antibodies or fragments thereof of any of claim 26 or 27, for use in therapy, in particular for use in passive immunization.

### Claim 31 (depends on 26, 27, 28)

The pharmaceutical composition of claim 28 or the antibodies or fragments thereof of any of claim 26 or 27, for use in a method of prophylactic treatment (before infection) and/or therapeutic treatment (after infection or after after the clinical manifestation of the disease caused by the infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition.

### Claim 32 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 26, 27, 28)

The pharmaceutical composition of any of claims 11-21 or claim 28 or the mutant live auxotrophic bacterial strain for D-glutamate of any of claim 22 or 23 or the antibodies or fragments thereof of any of claim 26 or 27, for use in a method of prophylactic treatment (before infection) and/or therapeutic treatment (after infection or after after the clinical manifestation of the disease caused by the infection) of animals and/or humans against infection with the wild type form of the mutant auxotrophic bacterial strain of the composition and wherein said composition, bacterial strain or antibody or fragment thereof is administered intranasally, intradermally, subcutaneously, orally, by aerosol, intramuscularly, wing web and eye-drop administration.

### Claim 33 (depends on 26, 27)

A kit or device comprising the antibody or fragment thereof of any of claim 26 or 27.

### Claim 34 (depends on 26, 27)

A kit or device for detecting an infection of bacterial origin through an immunoassay comprising:
(i) a first antibody called “capture antibody” as defined in any of claim 26 or 27, wherein said first antibody is preferably attached to a solid support;
(ii) a second labeled antibody called “detection antibody” which recognizes a region other than the region recognized by the first antibody , wherein said second antibody comprises a marker which may be fluorescent , luminescent or an enzyme;
(iii) a reagent showing affinity for the second antibody, said reagent being coupled to a first member of a binding pair; and
(iv) a second member of a binding pair coupled to a fluorescent, luminescent or an enzyme, wherein the binding pair is selected from the group consisting of: hapten and antibody; antigen and antibody; biotin and avidin; biotin and streptavidin; a biotin analogue and avidin; a biotin analogue and streptavidin; sugar and lectin; an enzyme and a cofactor; a nucleic acid or a nucleic acid analogue and the complementary nucleic acid or nucleic acid analogue.

### Claim 35 (depends on 33, 34)

Use of the kit or device of any of claim 33 or 34 for the qualitative and/or quantitative determination of bacterial species or bacterial strains in a biological sample from a mammal, in particular, in the plasma of a mammal suspected of suffering from a bacterial disease.

### Claim 36

A method of in vitro cultivation of bacterial strains auxotrophic for D-glutamate comprising the utilization of a concentration of D-glutamate between 0.00001 and 120 mM.

### Claim 37 (depends on 36)

The method of claim 36, wherein the concentration range of D-glutamate is between 0.01-50 mM.

### Claim 38 (depends on 37)

The method of claim 37, wherein the concentration range of D-glutamate is between 10-20 mM.
